ATE423136T1 - Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor - Google Patents

Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor

Info

Publication number
ATE423136T1
ATE423136T1 AT02804876T AT02804876T ATE423136T1 AT E423136 T1 ATE423136 T1 AT E423136T1 AT 02804876 T AT02804876 T AT 02804876T AT 02804876 T AT02804876 T AT 02804876T AT E423136 T1 ATE423136 T1 AT E423136T1
Authority
AT
Austria
Prior art keywords
csf
biologically active
isolation
stimulating factor
colony stimulating
Prior art date
Application number
AT02804876T
Other languages
English (en)
Inventor
Porekar Vladka Gaberc
Viktor Menart
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Application granted granted Critical
Publication of ATE423136T1 publication Critical patent/ATE423136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT02804876T 2001-12-19 2002-12-05 Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor ATE423136T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200100322A SI21102A (sl) 2001-12-19 2001-12-19 Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika

Publications (1)

Publication Number Publication Date
ATE423136T1 true ATE423136T1 (de) 2009-03-15

Family

ID=20433022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804876T ATE423136T1 (de) 2001-12-19 2002-12-05 Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten- koloniestimulierungsfaktor

Country Status (21)

Country Link
US (1) US20050159589A1 (de)
EP (2) EP2053061A1 (de)
JP (1) JP4454311B2 (de)
KR (1) KR20040071212A (de)
CN (1) CN1606568A (de)
AT (1) ATE423136T1 (de)
AU (1) AU2002366275B2 (de)
BR (1) BR0215191A (de)
CA (1) CA2469984C (de)
DE (1) DE60231243D1 (de)
HR (1) HRP20040572A2 (de)
HU (1) HUP0402547A3 (de)
IL (2) IL162448A0 (de)
MX (1) MXPA04006076A (de)
NO (1) NO20042967L (de)
NZ (1) NZ533305A (de)
PL (1) PL207775B1 (de)
RU (1) RU2358980C2 (de)
SI (2) SI21102A (de)
WO (1) WO2003051922A1 (de)
ZA (1) ZA200404291B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
DE60304435T2 (de) * 2004-01-19 2006-08-24 Ares Trading S.A. Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
JP5031370B2 (ja) * 2004-09-17 2012-09-19 セルジェンテック株式会社 外用皮膚潰瘍治療剤
EP1856147A4 (de) * 2005-02-15 2008-07-02 Apollo Life Sciences Ltd Molekül und chimere moleküle davon
EP1869078A2 (de) * 2005-03-17 2007-12-26 Zenotech Laboratories Limited Verfahren für die reinigung von rekombinantem granulocytenkoloniestimulierendem faktor
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP1878739A1 (de) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. Einstufige IMAC (MCAC) Aufreinigung von Proteinen
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
DK2197919T3 (da) 2007-08-27 2014-07-07 Ratiopharm Gmbh Flydende formulering af g-csf-konjugat
JP2009073819A (ja) * 2007-08-29 2009-04-09 Fujifilm Corp 生理活性物質の精製方法
WO2010146599A1 (en) * 2009-06-16 2010-12-23 Lupin Limited Process for purification of recombinant human granulocyte colony stimulating factor
KR101741859B1 (ko) 2009-06-22 2017-06-15 암젠 인크 화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
SI3660032T1 (sl) 2009-06-25 2026-02-27 Amgen Inc. Postopki zajemanja in čiščenja beljakovin, izraženih v nesesalskem sistemu
WO2011121031A1 (en) * 2010-03-30 2011-10-06 Octapharma Ag Process for the purification of a growth factor protein
JP6147726B2 (ja) 2011-03-29 2017-06-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ タンパク質精製のためのバッファー系
CN103215340A (zh) * 2012-01-19 2013-07-24 江苏粒福特生物科技有限公司 一种新颖的粒细胞制备及其抗癌活性检测方法
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
FI900178A0 (fi) * 1988-05-13 1990-01-12 Amgen Inc Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.
US5055555A (en) 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5932102A (en) 1998-01-12 1999-08-03 Schering Corporation Immobilized metal, affinity chromatography
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes

Also Published As

Publication number Publication date
AU2002366275A1 (en) 2003-06-30
MXPA04006076A (es) 2005-02-24
EP1458757B1 (de) 2009-02-18
RU2358980C2 (ru) 2009-06-20
IL162448A (en) 2010-12-30
SI21102A (sl) 2003-06-30
DE60231243D1 (de) 2009-04-02
AU2002366275B2 (en) 2009-04-02
CA2469984C (en) 2014-05-20
CN1606568A (zh) 2005-04-13
BR0215191A (pt) 2004-11-16
HRP20040572A2 (en) 2005-06-30
CA2469984A1 (en) 2003-06-26
HUP0402547A2 (hu) 2005-03-29
HK1064681A1 (en) 2005-02-04
NO20042967L (no) 2004-09-07
RU2004121982A (ru) 2005-04-20
NZ533305A (en) 2005-11-25
PL369669A1 (en) 2005-05-02
EP1458757A1 (de) 2004-09-22
IL162448A0 (en) 2005-11-20
US20050159589A1 (en) 2005-07-21
ZA200404291B (en) 2005-08-05
EP2053061A1 (de) 2009-04-29
HUP0402547A3 (en) 2010-01-28
PL207775B1 (pl) 2011-01-31
WO2003051922A1 (en) 2003-06-26
JP2005525304A (ja) 2005-08-25
JP4454311B2 (ja) 2010-04-21
KR20040071212A (ko) 2004-08-11
SI1458757T1 (sl) 2009-10-31

Similar Documents

Publication Publication Date Title
DE60231243D1 (de) Prozess für die aufreinigung und isolierung von biologisch-aktivem granulozyten-koloniestimulierungsfaktor
ATE226960T1 (de) Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung
DE60014047D1 (de) Verfahren zur reinigung von milchsäure auf industrieller basis
ATE363541T1 (de) Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
ATE452870T1 (de) (meth)acrylsaeurekristall und verfahren zur herstellung und aufreinigung von waessriger (meth)acrylsaeure
ATE403671T1 (de) Methoden zur aufreinigung von rekombinatem humanem erythropoietin aus zellkulturüberständen
DE58903791D1 (de) Peptidderivate, verfahren zu ihrer herstellung und ihre verwendung.
US20100286425A1 (en) Organic-inorganic hybrid chiral sorbent and process for the preparation thereof
ATE428728T1 (de) Verfahren zur reinigung von erythropoietin
DK1714982T3 (da) Fremgangsmåde til rensning af stærkt anioniske proteiner
CA2210990A1 (en) New combined process for the purification of vancomycin hydrochloride
KR20010080380A (ko) Ｌ-카르니틴의 산업적인 제조 방법
CA2147590A1 (en) A process for producing substituted amines and a method for purifying synthetic intermediates therefor
Ogura et al. An efficient 1, 3-asymmetric induction accompanied with epimerization at the 2-position. Stereoselective reduction of α-substituted β-keto sulfoxides under basic conditions
HRP20110948T1 (hr) Postupak za pročišćavanje il-18 vezujućeg proteina
DE3878577D1 (de) Verwendung von funktionellen polymerharzen als stationaere phase in der affinitaetschromatographie fuer die reinigung des wachstumsfaktors und entsprechendes reinigungsverfahren.
ATE522617T1 (de) Verfahren zur aufreinigung von interferon-beta
AU2003302418A1 (en) Method and apparatus for concentration and purification of nucleic acid
DE60039533D1 (de) Verbessertes verfahren zur herstellung von 2s,3s-n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin
DE69909091D1 (de) Chirale stationäre phasen für die trennung von enantiomeren und ihre herstellung
DE69001309D1 (de) Verfahren zur herstellung von antihaemophilem faktor (faktor viii), der eine hohe reinheit aufweist.
ATE461278T1 (de) Verfahren zur reinigung des modifizierten hauptallergens von milben
DE60233541D1 (de) Verfahren zur Reinigung von 5'-geschützten 2'-Deoxypurin Nukleosiden
NO20052916L (no) Fremgangsmate for rensingen av TNF-bindende proteiner ved anvendelse av IMAC
WO2025186218A8 (en) Purification and analysis of rna

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1458757

Country of ref document: EP